Cryopreserved vein may be a reasonable alternative conduit for limb salvage when no autogenous tissue is available; it has an acceptable limb salvage rate (62.3%) at 3 years. Long-term patency remains relatively poor, with only 23.6% of originally placed grafts patent at 3 years. The use of cryopreserved veins should be strictly confined to limb salvage after a thorough search for autogenous tissue has been exhausted.

RC-4 have fewer comorbidities, less advanced ischemia, and better outcome than RC-5. These groups should be evaluated individually. Limb salvage was acceptable, yet early wound healing without TER (SCS) occurred in only 21%. RC-5, DM, and CHF were predictors of poor SSCS. Careful selection of patients should improve outcome.

No abstract